Long‐term efficacy of canakinumab in hyperimmunoglobulin D syndrome
International Journal of Rheumatic Diseases · 2024-01 · 27 (1)
DOI: 10.1111/1756-185x.14857 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 14.08.2023. Verfasst von Ozlem Ozdemir Isik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kocaeli University, Kocaeli, Turkey. Hauptthemen laut MEDLINE: Mevalonate Kinase Deficiency, Familial Mediterranean Fever. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Hyperimmunoglobulin D syndrome (HIDS) is a rare autoinflammatory disorder with autosomal recessive inheritance. It is caused by specific mutations in the mevalonate kinase gene (MVK). No treatment specific to HIDS has been approved to date; however, nonsteroidal anti‐inflammatory drugs, steroids, colchicine, tumor necrosis factor‐α inhibitors, and anti‐interleukin‐1 treatments are used, based on case reports and observational studies. Herein, we report a case with recurrent fever and arthritis attacks who did not respond to anakinra and was successfully treated with canakinumab. Long‐term remission was achieved without any side effects with 300 mg canakinumab treatment every 4 weeks for 5 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kocaeli University, Kocaeli, Turkey.
- Division of Medical Genetics, Department of Internal Medicine, School of Medicine, Istanbul University, Istanbul, Turkey.
ORCID-Profile: Ozlem Ozdemir Isik, Duygu Temiz Karadag, Senem Tekeoglu, Ayten Yazici, Kıvanc Cefle, Ayse Cefle
Zitieren
APA
Ozdemir Isik, O., Karadag, D. T., Tekeoglu, S., Yazici, A., Cefle, K., & Cefle, A. (2024). Long‐term efficacy of canakinumab in hyperimmunoglobulin D syndrome. International Journal of Rheumatic Diseases, 27(1). https://doi.org/10.1111/1756-185x.14857
Vancouver
Ozdemir Isik O, Karadag DT, Tekeoglu S, Yazici A, Cefle K, Cefle A. Long‐term efficacy of canakinumab in hyperimmunoglobulin D syndrome. International Journal of Rheumatic Diseases. 2024;27(1). doi:10.1111/1756-185x.14857
BibTeX
@article{OzdemirIsik2024,
author = {Ozdemir Isik, Ozlem and Karadag, Duygu Temiz and Tekeoglu, Senem and Yazici, Ayten and Cefle, Kıvanc and Cefle, Ayse},
title = {Long‐term efficacy of canakinumab in hyperimmunoglobulin D syndrome},
journal = {International Journal of Rheumatic Diseases},
year = {2024},
volume = {27},
number = {1},
doi = {10.1111/1756-185x.14857}
}
EUVIMED